RxDoctor Payments Data

Loida Arquiza, APRN

Family · Kingman, AZNPI 1932732633

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 26 payments — averaging $53.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$389
  • Boston Scientific$231
  • Lilly USA, LLC$164
  • Sanofi-aventis U.S. LLC$150
  • Astellas Pharma US Inc$140
  • AbbVie$128
  • plus $180 from 4 others

What the payments were for

  • Speaking & faculty fees$15011%
  • Food & beverage$1,23389%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$135,698
Medicare patients
379
Services billed
2,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$122,003
MounjaroTirzepatide24$34,963
XareltoRivaroxaban23$32,884
EliquisApixaban21$32,222
JardianceEmpagliflozin17$28,784
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,697
MyrbetriqMirabegron15$17,839
Tresiba Flextouch U-100Insulin Degludec17$15,015
Tresiba Flextouch U-200Insulin Degludec11$10,720
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$7,143
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,353
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen161$4,660
Gabapentin204$4,133
Atorvastatin Calcium526$3,770
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen117$3,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$25$122,00386 claims
Lilly USA, LLCMounjaro$164$34,96324 claims
Astellas Pharma US IncMyrbetriq$140$17,83915 claims
AbbVieSynthroid$128$1,21124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.

Other family in Kingman

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →